Background: To effectively use pancreatic cancer patient-derived xenograft (PDX) models in translational research, successful PDX engraftment of surgical specimens in immune-deficient mice is needed.
Materials and methods: A total of 102 patients underwent pancreatic cancer resection using various procedures. Tumor tissue from all patents was implanted subcutaneously into mice. Tumor engraftment and growth in mice were determined. Engraftment was tested for correlation with operation type, time, tumor size, and oncogene expression using immunohistoculture.
Results: Multivariate analysis showed that a tumor size of more than 3.5 cm in the patient was a significant factor related to successful PDX engraftment. In contrast, there was no correlation of engraftment with surgical procedure, time needed to remove the specimen, tumor differentiation, lymph node metastasis, and protein expression of p53, Receptor tyrosine-protein kinase erbB-2 (CERBB2), or deleted in pancreatic carcinoma locus 4 (DPC4).
Conclusion: A minimum tumor size in the patient is an important factor for successful tumor engraftment.
Keywords: Pancreatic ductal adenocarcinoma; correlation; engraftment; non-SCID mice; patient; patient-derived xenografts; tumor resection; tumor size.
Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.